Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.
๏ปฟ

TSXV:VPT - Post by User

Comment by jopatcloon Aug 12, 2024 10:23am
69 Views
Post# 36174367

RE:RE:Really good news before ๐Ÿ‘€๐Ÿ‘๐Ÿš€ FDA V4.0 Dear Friend;

RE:RE:Really good news before ๐Ÿ‘€๐Ÿ‘๐Ÿš€ FDA V4.0 Dear Friend;
jopatclo wrote:
jopatclo wrote:
 Dear Friend;
 
I hope the summer break has been rejuvenating.  The team at Ventripoint has been working hard to complete the next generation of the VMS+ product family and submit it for approval.
 
Here is some background:
 
1. VMS+3.0 is our current model, which is being used in hospitals in Canada, USA, Europe and UK. (VMS+2.0 is being manufactured and used in leading hospitals in China through a partnership).
2. VMS+4.0 is the next regeneration model which incorporates a number of novel measurements of heart function as well as novel ways to view the data in three dimensions.  This newest version speeds up the analysis of the heart through AI-assisted point placements and automated view recognition. This makes the VMS+4.0 much easier to integrate into the standard workflow within an echocardiography service unit in a hospital, clinic or remote imaging center.
3. The company previously announced the submission to the US-FDA (see NR May 6, 2024). 
4. Today we are announcing the submission to Health Canada, which was filed a few weeks ago (see attached NR).  Health Canada typically responds more quickly than the US-FDA so expect this to move along quickly,
5. The Company is now preparing submissions for clearances in UK and EU (CE Mark).
6. The Company continues to engage existing users about the previously announced upgrade to VMS+3.2, which had an improved tracking component that did not have a magnet and so made the VMS+3.2 suitable for patients with ICDs like pacemakers and defibrillators.  The upgrade also allows for rapid linkage and calibration to all existing 2D ultrasound devices sold by OEM manufacturers.
7. The Company will continue to sell the VMS+3.2 as the “standard" device and intends to sell the VMS+4.0 as a “premium" device at a premium price, once it has received regulatory clearances.
 
Thank you for your continued interest and support as we continue to improve heart diagnostics for everyone, everywhere and especially for children born with heart defects.
 
Regards,
 
Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.
TSXV-VPT
www.ventripoint.com
519-803-6937

Interesting Point 1 and 7 
VMS+3.0 is our current model, which is being used in hospitals in Canada, USA, Europe and UK. (VMS+2.0 is being manufactured and used in leading hospitals in China through a partnership).
(premium price) 7. The Company will continue to sell the VMS+3.2 as the “standard" device and intends to sell the VMS+4.0 as a “premium" device at a premium price, once it has received regulatory clearances.


Good comment 

@cardinal You will see major clinics buy. Then you will see everyone else follow.
 
5
 
@yudi  Interesting Point 1 VMS+3.0 is our current model, which is being used in hospitals in Canada, USA, Europe and UK. (VMS+2.0 is being manufactured and used in leading hospitals in China through a partnership). And Interesting for those who have been masters in denigrating Ventripoint for years ! The visionary Dr. G. Adams and Alvira M. have done the long work that had to be done during all these years for Ventripoint to arrive V4.0 Bravo procurement in healthcare is complex . FDA V4.0 and Sales at any time now Insiders know!
 
1
 
@cardinal The usage is becoming very clear for hospitals now. Time and money are the number one factors and 4.0 addresses those. We also have reimbursement codes. Hugh and team are finishing the sales platform for client engagement, billing and tracking. slow going but this company is now being built to scale. watch for branding
 
5
 
@cardinal Hughes travel agent is likely buying .....
 
3
 
0
@cardinal You will see major clinics buy. Then you will see everyone else follow.
 
5
 
@yudi  Interesting Point 1 VMS+3.0 is our current model, which is being used in hospitals in Canada, USA, Europe and UK. (VMS+2.0 is being manufactured and used in leading hospitals in China through a partnership). And Interesting for those who have been masters in denigrating Ventripoint for years ! The visionary Dr. G. Adams and Alvira M. have done the long work that had to be done during all these years for Ventripoint to arrive V4.0 Bravo procurement in healthcare is complex . FDA V4.0 and Sales at any time now Insiders know!
 
1
 
@cardinal The usage is becoming very clear for hospitals now. Time and money are the number one factors and 4.0 addresses those. We also have reimbursement codes. Hugh and team are finishing the sales platform for client engagement, billing and tracking. slow going but this company is now being built to scale. watch for branding
 
5
 
@cardinal Hughes travel agent is likely buying .....
 
3
 
0

<< Previous
Bullboard Posts
Next >>